Accretion Nutraveda Ltd (544694) — Board Meeting | 1 September 2026

· BSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Board approved MOA amendments expanding business scope and financial powers
💡 Investor Takeaway
Shareholders must approve these changes, potentially enabling future growth in healthcare and finance sectors.

Accretion Nutraveda's board approved amendments to its Memorandum of Association to expand business scope into nutraceuticals, pharmaceuticals, and healthcare services, including new sub-clauses for financial activities and investments. The changes require shareholder approval via postal ballot under the Companies Act and SEBI regulations. The filing emphasizes regulatory compliance for operational flexibility in new markets.

📄 View Original Announcement (PDF)

About Accretion Nutraveda Ltd (544694)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹201.42 Cr

View full 544694 stock details →

📡 Get AI alerts when 544694 files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track 544694 — Free

📊 More 544694 filings

See all 544694 filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts for your stocks — summarized by AI daily

Set up your AI Radar — pick stocks, get daily email summaries of new filings.

Set up AI Radar — Free

Free account · 2 AI queries/day